首页> 美国卫生研究院文献>NPJ Genomic Medicine >A robust targeted sequencing approach for low input and variable quality DNA from clinical samples
【2h】

A robust targeted sequencing approach for low input and variable quality DNA from clinical samples

机译:针对临床样品中低输入量和质量可变的DNA的可靠靶向测序方法

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Next-generation deep sequencing of gene panels is being adopted as a diagnostic test to identify actionable mutations in cancer patient samples. However, clinical samples, such as formalin-fixed, paraffin-embedded specimens, frequently provide low quantities of degraded, poor quality DNA. To overcome these issues, many sequencing assays rely on extensive PCR amplification leading to an accumulation of bias and artifacts. Thus, there is a need for a targeted sequencing assay that performs well with DNA of low quality and quantity without relying on extensive PCR amplification. We evaluate the performance of a targeted sequencing assay based on Oligonucleotide Selective Sequencing, which permits the enrichment of genes and regions of interest and the identification of sequence variants from low amounts of damaged DNA. This assay utilizes a repair process adapted to clinical FFPE samples, followed by adaptor ligation to single stranded DNA and a primer-based capture technique. Our approach generates sequence libraries of high fidelity with reduced reliance on extensive PCR amplification—this facilitates the accurate assessment of copy number alterations in addition to delivering accurate single nucleotide variant and insertion/deletion detection. We apply this method to capture and sequence the exons of a panel of 130 cancer-related genes, from which we obtain high read coverage uniformity across the targeted regions at starting input DNA amounts as low as 10 ng per sample. We demonstrate the performance using a series of reference DNA samples, and by identifying sequence variants in DNA from matched clinical samples originating from different tissue types.
机译:下一代基因面板深度测序已被用作诊断测试,以鉴定癌症患者样品中可操作的突变。但是,临床样本(例如福尔马林固定,石蜡包埋的样本)通常会提供少量的降解,质量较差的DNA。为了克服这些问题,许多测序测定法都依赖于广泛的PCR扩增,从而导致偏差和伪影的积累。因此,需要一种靶向测序测定法,其可以在不依赖大量PCR扩增的情况下,以低质量和低数量的DNA表现良好。我们评估基于寡核苷酸选择性测序的靶向测序测定法的性能,该方法可以富集感兴趣的基因和区域,并从少量受损的DNA中鉴定序列变体。该测定利用适合于临床FFPE样品的修复过程,然后将衔接子连接至单链DNA和基于引物的捕获技术。我们的方法生成了高保真的序列库,并减少了对大量PCR扩增的依赖-除了提供准确的单核苷酸变体和插入/缺失检测之外,这还有助于准确评估拷贝数变化。我们应用这种方法来捕获和测序130个与癌症相关的基因的外显子,从中我们可以以低至每个样本10 ng的起始输入DNA量跨目标区域获得高阅读覆盖率。我们证明了使用一系列参考DNA样品的性能,并通过鉴定来自不同组织类型的匹配临床样品的DNA序列变异来证明其性能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号